Fig 1.
Inclusion criteria for full analytic cohort and sub-cohorts in the IBM Marketscan Commercial Database, 2007–2017.
Table 1.
Demographic characteristics of eculizumab recipients in the IBM Marketscan Commercial Database, overall and by indication for eculizumab use, 2007–2017.
Table 2.
Underlying conditions within the defined six-week window of 30 days before to 14 days after first documented eculizumab treatment among eculizumab recipients in the IBM Marketscan Commercial Database, 2007–2017.
Fig 2.
Percentage of eculizumab recipients receiving antibiotics for ≥50% of the risk period by year of starting eculizumab treatment, IBM Marketscan Commercial Database, 2007–2017.